ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2019

Good sales growth during May; Zinzino based revenue increased 21% and the total group revenue with a total of 10% compared with the previous year. 

The revenue for Zinzino's sales markets increased by 21% to SEK 58.6 (48.3) million due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 58% and amounted to SEK 3.3 (7.8) million due to high level of internal production during the month. Overall. the Group increased revenues by 10 % to SEK 61.9 (56.1) million compared with the previous year.

Accumulated income January - May increased by 21% to SEK 287.5 (238.5) million compared with the previous year.

Revenues distributed as follows:

Regions, SEK million 19 May 18 May Change YTD 2019 YTD 2018 Change
Baltic Markets 4.3 3.9 11% 22.1 17.9 23%
Nordic Markets 31.6 36.0 -12% 154.6 158.4 -2%
Europe Other Markets 20.2 6.6 208% 80.9 26.0 211%
North America 1.9 1.9 2% 9.4 8.2 15%
Australia 0.6 0.0 1.0 0.0
Zinzino 58.6 48.3 21% 268.0 210.5 27%
Faun Pharma 3.3 7.8 -58% 19.5 28.0 -30%
Zinzino Group 61.9 56.1 10% 287.5 238.5 21%

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information please contact:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700
zinzino.se 

Pictures for free publication:
Marcus Tollbom  +46 (0) 70-190 03 12

Certified Adviser:
Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se 

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 16:00 the 12th of June, 2019.

Tags:

About Us

Zinzino AB (publ.) is a direct sales company which operates through the EU, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns Norwegian BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has over 120 employees. The company has its registered office in Gothenburg, and offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public limited company and its shares are listed on Nasdaq First North.

Subscribe

Documents & Links